Related Experiment Videos
Improved detection of recurrent bladder cancer using the Bard BTA stat Test
M F Sarosdy1, M A Hudson, W J Ellis
1Division of Urology, University of Texas Health Science Center, San Antonio 78284-7845, USA.
Urology
|September 25, 1997
Summary
The BTA stat Test shows high sensitivity for detecting recurrent bladder cancer, significantly outperforming traditional cytology methods in urine analysis. This advancement improves early detection rates for bladder cancer recurrence.
Area of Science:
- Urology
- Oncology
- Diagnostic Medicine
Background:
- Recurrent bladder cancer detection is crucial for patient management.
- Current diagnostic methods like urine cytology have limitations in sensitivity.
Purpose of the Study:
- To evaluate the diagnostic performance of the BTA stat Test.
- To compare the BTA stat Test's efficacy against urine cytology and the original BTA Test for detecting recurrent bladder cancer.
Main Methods:
- The study assessed sensitivity and specificity using voided urine samples.
- Samples were collected from patients with recurrent bladder cancer, healthy volunteers, and patients with nonurologic conditions.
- Results were compared with cytology and the original BTA Test in a subgroup of cancer patients.
Main Results:
- The BTA stat Test detected 67% of recurrent bladder cancers.
- Compared to cytology (23%) and the original BTA Test (44%), the BTA stat Test demonstrated significantly higher sensitivity (58%) for cancer detection (P < 0.001).
- The specificity of the BTA stat Test was 72% for benign genitourinary conditions and 95% in healthy volunteers.
Conclusions:
- The BTA stat Test exhibits high sensitivity in detecting recurrent bladder cancer.
- It is significantly superior to voided urine cytology for this diagnostic purpose.